Home > Publications Database > Dataset: Data from: Metformin reverses early cortical network dysfunction and behavior changes in Huntington’s disease > print |
001 | 169082 | ||
005 | 20250127124930.0 | ||
024 | 7 | _ | |a 10.5061/DRYAD.G3B5272 |2 doi |
024 | 7 | _ | |a 10.5061/dryad.g3b5272 |2 doi |
037 | _ | _ | |a DZNE-2022-01789 |
041 | _ | _ | |a English |
100 | 1 | _ | |a Arnoux, Isabelle |b 0 |
245 | _ | _ | |a Dataset: Data from: Metformin reverses early cortical network dysfunction and behavior changes in Huntington’s disease |
260 | _ | _ | |c 2018 |b Dryad |
336 | 7 | _ | |a MISC |2 BibTeX |
336 | 7 | _ | |a Dataset |b dataset |m dataset |0 PUB:(DE-HGF)32 |s 1737978554_6605 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a Chart or Table |0 26 |2 EndNote |
336 | 7 | _ | |a Dataset |2 DataCite |
336 | 7 | _ | |a DATA_SET |2 ORCID |
336 | 7 | _ | |a ResearchData |2 DINI |
520 | _ | _ | |a Catching primal functional changes in early, “very far from disease onset” (VFDO) stages of Huntington’s disease is likely to be the key to a successful therapy. Focusing on VFDO stages, we assessed neuronal microcircuits in premanifest Hdh150 knock-in mice. Employing in vivo two-photon Ca2+ imaging, we revealed an early pattern of circuit dysregulation in the visual cortex- one of the first regions affected in premanifest Huntington’s disease - characterized by an increase in activity, an enhanced synchronicity and hyperactive neurons. These findings are accompanied by aberrations in animal behavior. We furthermore show that the anti-diabetic drug metformin diminishes aberrant Huntingtin protein load and fully restores both, early network activity patterns and behavioral aberrations. This network-centered approach reveals a critical window of vulnerability far before clinical manifestation and establishes metformin as a promising candidate for a chronic therapy starting early in premanifest Huntington’s disease pathogenesis long before the onset of clinical symptoms. |
536 | _ | _ | |a 351 - Brain Function (POF4-351) |0 G:(DE-HGF)POF4-351 |c POF4-351 |f POF IV |x 0 |
536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 1 |
588 | _ | _ | |a Dataset connected to DataCite |
650 | _ | 7 | |a cortical microcircuits |2 Other |
650 | _ | 7 | |a Huntington disease |2 Other |
650 | _ | 7 | |a in vivo calcium imaging |2 Other |
650 | _ | 7 | |a metformin |2 Other |
650 | _ | 7 | |a neuronal hyperactivity |2 Other |
700 | 1 | _ | |a Willam, Michael |b 1 |
700 | 1 | _ | |a Griesche, Nadine |0 P:(DE-2719)2690834 |b 2 |u dzne |
700 | 1 | _ | |a Krummeich, Jennifer |0 P:(DE-2719)2812064 |b 3 |u dzne |
700 | 1 | _ | |a Watari, Hirofumi |b 4 |
700 | 1 | _ | |a Offermann, Nina |0 P:(DE-2719)2811777 |b 5 |u dzne |
700 | 1 | _ | |a Weber, Stephanie |0 P:(DE-2719)2662310 |b 6 |u dzne |
700 | 1 | _ | |a Narayan Dey, Partha |b 7 |
700 | 1 | _ | |a Chen, Chen |b 8 |
700 | 1 | _ | |a Monteiro, Olivia |b 9 |
700 | 1 | _ | |a Buettner, Sven |0 P:(DE-2719)2809898 |b 10 |u dzne |
700 | 1 | _ | |a Meyer, Katharina |0 P:(DE-2719)2401927 |b 11 |u dzne |
700 | 1 | _ | |a Bano, Daniele |0 P:(DE-2719)2158358 |b 12 |u dzne |
700 | 1 | _ | |a Radyushkin, Konstantin |b 13 |
700 | 1 | _ | |a Langston, Rosamund |b 14 |
700 | 1 | _ | |a Lambert, Jeremy J. |0 P:(DE-HGF)0 |b 15 |
700 | 1 | _ | |a Wanker, Erich |b 16 |
700 | 1 | _ | |a Methner, Axel |b 17 |
700 | 1 | _ | |a Krauss, Sybille |0 P:(DE-2719)2421562 |b 18 |u dzne |
700 | 1 | _ | |a Schweiger, Susann |b 19 |
700 | 1 | _ | |a Stroh, Albrecht |b 20 |
773 | _ | _ | |a 10.5061/dryad.g3b5272 |
909 | C | O | |p VDB |o oai:pub.dzne.de:169082 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2690834 |
910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 3 |6 P:(DE-2719)2812064 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2811777 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 6 |6 P:(DE-2719)2662310 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)2809898 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 11 |6 P:(DE-2719)2401927 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2158358 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 15 |6 P:(DE-HGF)0 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 18 |6 P:(DE-2719)2421562 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-351 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Brain Function |x 0 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 1 |
914 | 1 | _ | |y 2018 |
920 | 1 | _ | |0 I:(DE-2719)1011006 |k AG Krauß |l Regulatory RNA-protein interaction in neurodegenerative diseases |x 0 |
920 | 1 | _ | |0 I:(DE-2719)1013003 |k AG Bano |l Aging and Neurodegeneration |x 1 |
920 | 1 | _ | |0 I:(DE-2719)1013033 |k AG Capasso |l Immune Regulation |x 2 |
920 | 1 | _ | |0 I:(DE-2719)1040300 |k Biorepository |l Biorepository |x 3 |
980 | _ | _ | |a dataset |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-2719)1011006 |
980 | _ | _ | |a I:(DE-2719)1013003 |
980 | _ | _ | |a I:(DE-2719)1013033 |
980 | _ | _ | |a I:(DE-2719)1040300 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|